Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 101

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4A
Chunk 101
---
  Revenues                          $                                    3,791      $                             1,075          487         287        5,640  
  Operating loss                    $                                  (11,100      $                               (39      (10,349      (5,020      (26,508  
  Year ended December 31, 2022                                                                                                                                 
  Revenues                          $                                      876      $                                72          513         214        1,675  
  Operating loss                    $                                  (12,256      $                              (220       (8,875      (5,590      (26,941  

A. Operating
Results

The following table sets forth our overall results of operations
(on an unsegmented basis) for the years ended December 31, 2022, 2023 and 2024. The below discussion of our results of operations omits
a comparison of our results for the years ended December 31, 2022 and 2023. In order to view that discussion, please see “ Item 5.
Operating and Financial Review and Prospects - A. Operating Results - Comparison of Period-to-Period Results of Operations”
in our Annual Report on Form 20-F for the year ended December 31, 2023, which we filed with the SEC on March 28, 2024.

                                                      2024                   2023                                            
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Consolidated Statements of Comprehensive loss:                                                                             
  ( U. S. dollars, in thousands)                                                                                             
  Revenues                                            $         8,511        $         5,640                1,675            
  Cost of revenues                                              2,683                  1,692                909              
  Gross profit                                                  5,828                  3,948                766              
  Operating expenses (income):                                                                                               
  Research and development, net                                 16,648                 20,777               20,792           
  Sales and marketing                                           3,425                  3,611                3,933            
  General and administrative                                    7,441                  6,068                6,482            
  Other expenses (income)                                       524                    -                    (3,500       )   
  Total operating expenses, net                                 28,038                 30,456               27,707           
  Operating loss                                                (22,210                (26,508      )